Close
-
About
About This Event
PANAO 2026 has concluded, but its impact is just beginning.
Each year, the Practical Applications of New Agents in Oncology (PANAO) conference brings together leading oncology and hematology experts to examine emerging therapies, clinical data and evolving treatment strategies shaping the future of cancer care.
Since its founding in 1999, PANAO has served as a national forum for translating scientific discovery into clinical practice — connecting physicians, researchers and the broader oncology and hematology care teams around a shared commitment to advancing care for the patients we serve.
We look forward to welcoming you to PANAO 2027.
-
Agenda
Agenda
Thursday, Feb. 12, 2026 (Day 1) 7–7:50 a.m. Registration and Breakfast 7:50–8 a.m. Opening Remarks: Daruka Mahadevan, MD, PhD, UT Health San Antonio, Mays Cancer Center 8–8:45 a.m. Special Session: Inaugural Dan Von Hoff Lectureship | Moderator: Daruka Mahadevan, MD, PhD, UT Health San Antonio, Mays Cancer Center 8–8:40 a.m. Unexplored Frailties of Cancer | Daniel Von Hoff, MD, TGEN, Arizona 8:40–8:45 a.m. Questions & Answers 8:45–8:55 a.m. Break 8:55–10:35 a.m. Session 1: Therapeutic Advances in GI Cancers | Moderator: Georgios Fotopoulos, MD, PhD, UT Health San Antonio, Mays Cancer Center 8:55–9:25 a.m. Advances in Liver Cancer | Sukeshi Arora, MD, UT Health San Antonio 9:25–9:55 a.m. CAR T Cell Therapies in Hepatocellular Carcinoma | Anuradha Krishnamurthy, MD, Roswell Park 9:55–10:25 a.m. Advances in Colorectal Cancer | Sreenivasa Chandana, MD, PhD, START, Grand Rapids, MI 10:25–10:35 a.m. Questions & Answers 10:35–10:55 a.m. Break 10:55–12:30 p.m. Session 2: Novel Agents in Drug Development | Moderator: John Sarantopoulos, MD, UT Health San Antonio 10:55–11:25 a.m. Current Advances in Antibody Drug Conjugates | Daruka Mahadevan, MD, PhD, UT Health San Antonio 11:25–11:55 a.m. Recent Advances in Bispecific Antibodies in Lung Cancer | Kai He, MD, PhD, Ohio State University 11:55–12:25 p.m. Advances in Protein Degradation | Jin Wang, PhD, Baylor College of Medicine 12:25–12:30 p.m. Questions & Answers 12:30–1:40 p.m. Lunch, Networking and Exhibition 1:40–3:30 p.m. Session 3: AI in Therapeutic Target Identification and New Drug Discovery | Moderator: Daruka Mahadevan, MD, UT Health San Antonio 1:40–2:10 p.m. Rethinking Data Access and Analytics for Novel Therapeutic Targets | Ritu Pandey, PhD, University of Arizona 2:10–2:50 p.m. Molecular Case Report | Jay Parekh, MD, UT Health San Antonio AI in Precision Medicine | Jeanne Kowalski, PhD, UT Austin 2:50–3:20 p.m. Accelerating Drug Discovery with AI | Dmytro Kovalskyy, PhD, UT Health San Antonio 3:20–3:30 p.m. Questions & Answers 3:30–3:50 p.m. Break 3:50–5:30 p.m. Session 4: Immune and Cellular Therapies for GU Cancers | Moderator: John Sarantopoulos, MD, UT Health San Antonio 3:50–4:20 p.m. Implications of I RAE and Discontinuation of Immune Checkpoint Inhibitor Therapy in RCC Patients | Saby George, MD, Roswell Park 4:20–4:50 p.m. Driving Towards a Cure in Genitourinary Cancers with Cellular Therapy | Benjamin Maughan, MD, PharmD, University of Utah 4:50–5:20 p.m. Updates in the Management of AML | Eytan Stein, MD, Memorial Sloan Kettering Cancer Center 5:20–5:30 p.m. Questions & Answers 5:30 p.m. Day 1 Adjournment Friday, Feb. 13, 2026 (Day 2) 7–8 a.m. Registration, Breakfast & Exhibits 8– 9:40 a.m. Session 5: Advances of Drug Development in Hematology | Moderator: Zohra Nooruddin, MD, UT Health San Antonio, Mays Cancer Center 8– 8:30 a.m. Lymphoma | Julio Chavez, MD, Mayo Clinic 8:30– 9:00 a.m. MDS | Guillermo Garcia-Manero, MD, MD Anderson 9–9:30 a.m. Benign Hematology | Usha Perepu, MD, UT Health San Antonio 9:30–9:40 a.m. Questions & Answers 9:40–10:10 a.m. Break 10:10 a.m. -11:50 a.m. Session 5: Moderator: Georgios Fotopoulos, MD, PhD, UT Health San Antonio, Mays Cancer Center 10:10–10:40 a.m. New Agents-New Strategies in 2026 | Marcela Mazo Canola, MD, UT Health San Antonio 10:40–11:10 a.m. Sarcoma | Catherine Wilbur, MD, Johns Hopkins 11:10–11:40 a.m. Targeting RAS: What have we learned? What are we learning? What do we need to learn? | David Hong, MD, MD Anderson 11:40 a.m. – 11:50 a.m. Questions & Answers 11:50 a.m. –1 p.m. Lunch, Networking and Exhibition 1–1:35 p.m. Session 6: Research Award | Moderator: John Sarantopoulos, MD, UT Health San Antonio, Mays Cancer Center 1–1:15 p.m. Overcoming Barriers to Enrollment in Phase 1 Oncology Clinical Trials | Avery Alva, RN, UT Health San Antonio 1:15–1:20 p.m. Questions & Answers 1:20–1:25 p.m. Award Presentation and Closing Remarks | Daruka Mahadevan, MD, PhD and John Sarantopoulos, MD 1:30 p.m. Close of Program -
Date and Time
Date and Time
-
Location
Location
Embassy Suites by Hilton San Antonio Landmark
5615 Landmark Parkway
Book your room through the conference room block and save
San Antonio, TX, 78249
*Free on-site parking is provided for all attendees -
Contact
Contact
For questions about the conference, please send an email to PANAO@uthscsa.edu
-
Exhibitor Details
Exhibitor Details
-
Registration
PANAO 2026 has concluded. Thank you for joining us. Registration details for PANAO 2027 coming soon.